Research programme: T cell receptor cancer therapeutics - Kite Pharma/Leiden University Medical Center

Drug Profile

Research programme: T cell receptor cancer therapeutics - Kite Pharma/Leiden University Medical Center

Latest Information Update: 13 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kite Pharma; Leiden University Medical Center
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Cell replacements; T-cell receptor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 13 May 2016 9195659- relevant info already updated
  • 13 Jan 2016 Kite Pharma and Leiden University Medical Center agree to co-develop T-cell receptor therapeutics for Cancer
  • 13 Jan 2016 Early research in Solid tumours in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top